955 related articles for article (PubMed ID: 1141431)
1. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
2. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.
Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K
Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of properdin in normal subjects and patients with renal disease.
Ziegler JB; Rosen FS; Alper CA; Grupe W; Lepow IH
J Clin Invest; 1975 Sep; 56(3):761-7. PubMed ID: 1159085
[TBL] [Abstract][Full Text] [Related]
4. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
Adu D; Williams DG
Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
[TBL] [Abstract][Full Text] [Related]
5. The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis.
Garin EH; Donnelly WH; Shulman ST; Fernandez R; Finton C; Williams RL; Richard GA
Clin Nephrol; 1979 Oct; 12(4):148-55. PubMed ID: 315852
[TBL] [Abstract][Full Text] [Related]
6. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
7. [Activation of the complement system in different forms of glomerulonephritis].
Wegmüller E; Frey B; Hodler J
Schweiz Med Wochenschr; 1977 Jul; 107(29):1028-34. PubMed ID: 331469
[TBL] [Abstract][Full Text] [Related]
8. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
9. Studies of serum complement in the hypocomplementaemic nephritides.
Williams DG; Peters DK; Fallows J; Petrie A; Kourilsky O; Morel-Maroger L; Cameron JS
Clin Exp Immunol; 1974 Nov; 18(3):391-405. PubMed ID: 4219908
[TBL] [Abstract][Full Text] [Related]
10. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN).
Geiger H; Good RA; Day NK
Clin Nephrol; 1975; 3(4):139-47. PubMed ID: 1149337
[TBL] [Abstract][Full Text] [Related]
11. Serum and glomerular complement in 205 cases of glomerulonephritis.
Durante A; Rovati C; di Belgiojoso GB; Minetti L
Proc Eur Dial Transplant Assoc; 1976; 12():189-96. PubMed ID: 935112
[TBL] [Abstract][Full Text] [Related]
12. Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis.
Andres GA; Accinni L; Beiser SM; Christian CL; Cinotti GA; Erlanger BF; Hsu KC; Seegal BC
J Clin Invest; 1970 Nov; 49(11):2106-18. PubMed ID: 4097660
[TBL] [Abstract][Full Text] [Related]
13. Breakdown products of C3 and factor B in hemolytic-uremic syndrome.
Kim Y; Miller K; Michael AF
J Lab Clin Med; 1977 Apr; 89(4):845-50. PubMed ID: 845484
[TBL] [Abstract][Full Text] [Related]
14. Determination of complement breakdown fragments C3d and its subfragments in health and disease.
Tamotsu M; Arai K; Fujita S; Hosotsubo K; Hayashi C; Miyai K; Miyano A; Kawanaka K; Takenaka M; Shimizu A
Diagn Immunol; 1984; 2(2):116-21. PubMed ID: 6333963
[TBL] [Abstract][Full Text] [Related]
15. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
16. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
Arroyave CM; Wilson MR; Tan EM
J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
[TBL] [Abstract][Full Text] [Related]
17. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
[TBL] [Abstract][Full Text] [Related]
19. Activation of the alternative complement pathway in systemic lupus erythematosus.
Wilson MR; Arroyave CM; Nakamura RM; Vaughan JH; Tan EM
Clin Exp Immunol; 1976 Oct; 26(1):11-20. PubMed ID: 826360
[TBL] [Abstract][Full Text] [Related]
20. Reduction of phagocyte adherence by nephritic sera: relation to complement activation.
Strife CF; Ruley EJ
Pediatr Res; 1984 Jul; 18(7):637-42. PubMed ID: 6332298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
